---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-067013"
form_type: "8-K"
ticker: "FDMT"
cik: "0001650648"
company_name: "4D Molecular Therapeutics, Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T04:40:43.190014+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# 4DMT Q1 net loss $48M; initiates 4D-150 Phase 3 in wet AMD; cash runway to 2028

## Summary
- Net loss $48.0M vs $32.4M YoY; R&D expenses $40.7M (+46% YoY) due to Phase 3 startup.
- Cash $458M (down from $505M Dec 2024); expected to fund operations into 2028.
- First patients enrolled in 4D-150 Phase 3 (4FRONT-1) in wet AMD; 4FRONT-2 starts Q3 2025; topline H2 2027.
- FDA RMAT designation for 4D-150 in DME; FDA aligned on single Phase 3 trial for BLA.
- Pipeline focused on 4D-150 and 4D-710; paused/terminated 4D-175, 4D-725, 4D-310, 4D-110, 4D-125.

## SEC filing metadata
- accession: 0000950170-25-067013
- form_type: 8-K
- ticker: FDMT
- cik: 0001650648
- company_name: 4D Molecular Therapeutics, Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650648/000095017025067013/0000950170-25-067013-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650648/000095017025067013/fdmt-20250508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-067013
- JSON: https://secwatch.observer/filing/0000950170-25-067013.json
- Plain text: https://secwatch.observer/filing/0000950170-25-067013.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.